Deliver Your News to the World

FDA acquires GEA ConsiGma 1 unit for their CDER/OPQ Continuous Lab


WEBWIRE

The FDA has purchased a GEA ConsiGma™ 1 OSD development unit, which is housed in the CDER/OPQ (Office of Pharmaceutical Quality). The GEA ConsiGma™ 1 will be an important asset for continuous manufacturing research within the OPQ Office of Testing and Research and Emerging Technologies Team.

The FDA/CDER/OPQ mission is to ensure that safe, effective, high quality drugs are available for the American public. Established in 2015, OPQ encourages and supports development and adoption of emerging technology to modernize pharmaceutical development and manufacturing.

In development, scientist and engineers need to investigate the capability of their processes and develop strategies to avoid or manage the effects variability from various sources. The GEA ConsiGma™ 1 enables development of granules following QbD principles via fast DOE approaches with controlled continuous operation, providing an opportunity to explore a wider range of process parameters with less product and less time. The result is much better process understanding in a shorter time and with lower costs.

About GEA

GEA is one of the largest suppliers of process technology for the food industry and a wide range of other industries. The international technology group focuses on process technology and components for sophisticated production processes in various end-user markets.

In 2017, GEA generated consolidated revenues of about EUR 4.6 billion. The food and beverages sector, which is a long-term growth industry, accounted for around 70 percent. The company employs almost 18,000 people worldwide. GEA is a market and technology leader in its business areas. The company is listed on the German MDAX stock index (G1A, WKN 660 200) and included in the STOXX® Europe 600 Index. In addition, the company is listed in selected MSCI Global Sustainability Indexes.


( Press Release Image: https://photos.webwire.com/prmedia/7/219848/219848-1.jpg )


WebWireID219848





This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.